AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Foghorn Therapeutics Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00HFZPB97
2.00▼ 0.01 (-0.50%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
2.01
Day's Range
1.90 – 2.04
52-Week Range
1.79 – 7.61
Volume
486.8K
Avg Volume
1.1M
Share Statistics
Shares Outstanding
Employees
106
Exchange
XNAS
Listed
2020-10-23
Share count as of July 31, 2026

Foghorn Therapeutics Inc. Common Stock (FHTX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Foghorn Therapeutics Inc. Common Stock (FHTX)
What is Foghorn Therapeutics Inc. Common Stock's Market Cap?
Foghorn Therapeutics Inc. Common Stock's Market Cap is $118.8M, based on as-reported figures from SEC (XBRL) filings.
What is Foghorn Therapeutics Inc. Common Stock's Price / Sales?
Foghorn Therapeutics Inc. Common Stock's Price / Sales is 3.2×, based on as-reported figures from SEC (XBRL) filings.
What is Foghorn Therapeutics Inc. Common Stock's Revenue (TTM)?
Foghorn Therapeutics Inc. Common Stock's Revenue (TTM) is $36.7M, based on as-reported figures from SEC (XBRL) filings.
What is Foghorn Therapeutics Inc. Common Stock's Net Income (TTM)?
Foghorn Therapeutics Inc. Common Stock's Net Income (TTM) is -$64.6M, based on as-reported figures from SEC (XBRL) filings.
What is Foghorn Therapeutics Inc. Common Stock's EBITDA?
Foghorn Therapeutics Inc. Common Stock's EBITDA is -$70.6M, based on as-reported figures from SEC (XBRL) filings.
What is Foghorn Therapeutics Inc. Common Stock's Diluted EPS (TTM)?
Foghorn Therapeutics Inc. Common Stock's Diluted EPS (TTM) is -1.09, based on as-reported figures from SEC (XBRL) filings.
What is Foghorn Therapeutics Inc. Common Stock's EBITDA Margin?
Foghorn Therapeutics Inc. Common Stock's EBITDA Margin is -192.3%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · FHTXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Collaboration revenue
YoY growth+112.7%-45.1%+223.8%+4.4%
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue154.8%760.3%358.2%326.9%
Loss from operations
% of revenue-54.8%-660.3%-258.2%-226.9%
Other income, net:
Interest income
Other income (expense), net——
Total other income, net
Net loss
% of revenue-44.7%-608.4%-234.3%-194.4%
Net loss per share attributable to common stockholders—basic (in dollars per share)
Net loss per share attributable to common stockholders—diluted (in dollars per share)